Immunotherapy and Immune Checkpoint Inhibitors
Updates in PD-1/PD-L1 and CTLA-4 immune checkpoint inhibition in NSCLC
Immune checkpoint inhibitors in the first-line setting for NSCLC
Evaluating the landscape of emerging PD-1/PD-L1 inhibitors
Novel immune checkpoint inhibitor-based combination therapies
Overcoming checkpoint inhibitor resistance with the next generation of immune checkpoint inhibitors targeting: TIGIT, CD73, CD27, LAG3, TIM3
Approved and Emerging Tyrosine Kinase Inhibitors and Other Targeted Agents
Approved and emerging agents targeting EGFR driver mutations
Updates in the pathophysiology of EGFR-driven NSCLC Emerging role of EGFR TKIs in the adjuvant and neoadjuvant setting
Novel EGFR TKI combination therapies
Strategies for overcoming EGFR TKI resistance
Targeting KRAS signaling with KRAS G12C, pan-KRAS, and SHP-2 inhibitors
Understanding the next-generation ALK TKI treatment landscape and integrating it into practice
Approved and emerging agents for MET-driven NSCLC
Targeting MET amplification and MET exon 14 skipping NSCLC
Approved and emerging agents targeting NTRK, RET, and ROS Targeting tumor cell metabolism through inhibition of KEAP1
Emerging Antibody Drug Conjugates, Antibodies, and CAR-T Therapy
Antibody drug conjugates targeting: TROP2, cMET, HER2, HER3
Investigational antibodies targeting vascular endothelial growth factor and combinations with immunotherapy
Updates on autologous tumor-infiltrating lymphocyte cell therapy
Recent developments in genetically modified T cell therapy for advanced NSCLC
Emerging bispecific antibodies and T cell-engaging bispecific antibodies targeting: PSMA, cMET, EGFR, HER2, HER3, DLL3
The role of dendritic cell vaccines for lung cancer immunotherapy
Small Cell Lung Cancer and Mesothelioma
Updates on chemotherapy and immunotherapy for small cell lung cancer
Understanding the pathophysiology of lineage plasticity and phenotype transition in SCLC
Mutational profiling, novel pathways, and novel targets for SCLC
Updates on diagnostic and prognostic biomarkers for SCLC
Emerging agents for SCLC
Updates on multimodal therapy, chemotherapy, and immunotherapy for malignant mesothelioma
Mutational profiling, novel pathways, and novel targets for malignant mesothelioma
Understanding the factors involved in chemoresistance in malignant mesothelioma Emerging agents for malignant mesothelioma
Dava Oncology • 2700 W. Plano Pkwy. • Plano, TX 75075 • USA
www.davaonc.com